ClinVar Miner

Submissions for variant NM_000384.3(APOB):c.9770A>G (p.Asn3257Ser)

gnomAD frequency: 0.00001  dbSNP: rs146178619
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV001838239 SCV000963073 likely benign Hypercholesterolemia, autosomal dominant, type B; Familial hypobetalipoproteinemia 1 2023-11-22 criteria provided, single submitter clinical testing
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV001811505 SCV002050177 uncertain significance not provided 2021-07-17 criteria provided, single submitter clinical testing The APOB c.9770A>G; p.Asn3257Ser variant (rs146178619), to our knowledge, is not reported in the medical literature but is reported in ClinVar (Variation ID: 664229). This variant is found in the non-Finnish European population with an allele frequency of 0.01% (12/113,532 alleles, including 0 homozygotes) in the Genome Aggregation Database. The asparagine at codon 3257 is moderately conserved, and computational analyses are uncertain whether this variant is neutral or deleterious (REVEL: 0.271). Due to limited information, the clinical significance of the APOB c.9770A>G; p.Asn3257Ser variant is uncertain at this time.
Ambry Genetics RCV003372885 SCV004096068 uncertain significance Cardiovascular phenotype 2023-08-08 criteria provided, single submitter clinical testing The p.N3257S variant (also known as c.9770A>G), located in coding exon 26 of the APOB gene, results from an A to G substitution at nucleotide position 9770. The asparagine at codon 3257 is replaced by serine, an amino acid with highly similar properties. This variant has been detected in an individual with hypercholesterolemia and in a myocardial infarction cohort (Rieck L et al. Clin Genet, 2020 Nov;98:457-467; Pan-Lizcano R et al. Int J Mol Sci, 2022 Dec;23). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.